SUBSCRIBE
SUBSCRIBE

GLP-1

Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Genetown
Boston ‘Unicorn’ Intarcia Banks a Whopping $215 Million to Support Diabetes Drug Pump
September 16, 2016
 · 
3 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Biotech Beach
2 High-Risk Biotechs Ready to Rock—Maybe
August 30, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Merrion Pharma Looks to Wind Up Operations, Announces Liquidation Plans
August 23, 2016
 · 
2 min read
With Hopes of Bolstering Sanofi’s Sagging Diabetes Sector, Announces FDA Approval of Adlyxin in U.S.
FDA
With Hopes of Bolstering Sanofi’s Sagging Diabetes Sector, Announces FDA Approval of Adlyxin in U.S.
July 28, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Novo Nordisk A/S Investors Disappointed as Top Selling Drug Victoza Didn’t Do as Well as Expected
June 14, 2016
 · 
2 min read
Job Trends
Intarcia to Move HQ Next Month, Plans to Double Workforce By End of 2017
June 14, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
As Part of Worldwide Expansion, Novo Nordisk A/S Spends 100 Million Euros to Build in France
April 21, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Eli Lilly Abandons Development of Transition Therapeutics’ Diabetes Candidate TT401
April 18, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Bay Area Startup Rani Therapeutics Tops $70 Million in Funding With Heavy Hitters like AstraZeneca PLC, Novartis AG and Google
February 24, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Sanofi Pays $20 Million Milestone and Redeems Priority Review Voucher for Zealand Pharma ’s LixiLan
December 23, 2015
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
August 29, 2025
 · 
10 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
August 26, 2025
 · 
11 min read
Press Releases
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
August 20, 2025
 · 
7 min read
Press Releases
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
August 19, 2025
 · 
15 min read
Press Releases
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
August 18, 2025
 · 
3 min read
Press Releases
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 18, 2025
 · 
7 min read
Press Releases
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
August 18, 2025
 · 
3 min read
Press Releases
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 14, 2025
 · 
11 min read
Press Releases
Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management
August 14, 2025
 · 
6 min read
Press Releases
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
August 13, 2025
 · 
8 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
August 7, 2025
 · 
10 min read
Press Releases
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
August 6, 2025
 · 
3 min read
Press Releases
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
August 6, 2025
 · 
8 min read
Press Releases
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 6, 2025
 · 
12 min read
Press Releases
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
August 6, 2025
 · 
5 min read
Press Releases
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
August 5, 2025
 · 
9 min read
Press Releases
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
August 5, 2025
 · 
8 min read
Press Releases
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
August 5, 2025
 · 
5 min read
Press Releases
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
July 30, 2025
 · 
7 min read
Press Releases
Hohenstein Medical Earns GLP Certification for Medical Device Testing
July 30, 2025
 · 
3 min read
Load More